Galvin, Robert http://orcid.org/0000-0001-7139-9707
Watson, Adrienne L.
Largaespada, David A.
Ratner, Nancy
Osum, Sara
Moertel, Christopher L.
Article History
Accepted: 18 January 2021
First Online: 15 March 2021
Declarations
:
: Robert Galvin, Nancy Ratner, and Christopher L. Moertel declare no conflict of interest. Adrienne L. Watson is an employee and shareholder of Recombinetics, Inc., and is supported by a grant from the Children's Tumor Foundation. David A. Largaespada is the co-founder and co-owner of several biotechnology companies including NeoClone Biotechnologies, Inc., Discovery Genomics, Inc. (recently acquired by Immusoft, Inc.), B-MoGen Biotechnologies, Inc. (recently acquired by Bio-Techne Corporation), and Luminary Therapeutics, Inc. He holds equity in, serves as a Senior Scientific Advisor for and Board of Director member for Recombinetics, a genome editing company. The business of all these companies is unrelated to the contents of this article. He consults for Genentech, Inc., which funds some of his research. Sara Osum is supported by a grant from the Children's Tumor Foundation.
: This article does not contain any studies with human or animal subjects performed by the authors.